Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
Zealand Pharma has announced corrections regarding its previous release about transactions in its securities by managerial personnel. The corrected share price at market close on May 12, 2022, was reported at DKK 73.75, lower than the previously stated DKK 75.75. This change affects the overall calculated value for participants involved in the transactions. Zealand Pharma, focusing on peptide-based medicines, currently has two marketed drugs and several candidates in late-stage development.
- Two marketed drugs (V-Go and Zegalogue) providing revenue streams.
- Three drug candidates in late-stage development, indicating potential growth.
- Correction in share price indicates potential volatility or miscommunication among management.
Company announcement – No. 20/ 2022
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities. The previous announcement 19 dated 12 May 2022, provided the share price at DKK 75.75, the actual share price at market close was DKK 73.75, which reduces the overall calculated value for each participant, as set out in the attached documentation.
Please see the attached corrected files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In the US Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
Attachments
- 61_220512_Notification_AdamSteensberg_psu
- 62_220512_Notification_IvanMoeller_psu
- 63_220512_Notification_ChristinaSBredal_psu
FAQ
What is the correct share price of Zealand Pharma on May 12, 2022?
What does Zealand Pharma specialize in?
How many drug candidates has Zealand Pharma advanced into clinical development?
What are the marketed products of Zealand Pharma?
What were the implications of the correction in Zealand Pharma's share price?
